Created at	Source	Raw Value	Validated value
March 12, 2022, midnight	usa	Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody;Local reactions and systemic events;Medically attend adverse events (MAAEs), serious adverse events (SAEs), adverse event of special interests (AESIs) and antibody dependent enhancements (ADEs);Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody;Unsolicited adverse events	Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody;Local reactions and systemic events;Medically attend adverse events (MAAEs), serious adverse events (SAEs), adverse event of special interests (AESIs) and antibody dependent enhancements (ADEs);Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody;Unsolicited adverse events
Oct. 29, 2021, 11:30 a.m.	usa	Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody;Safety evaluation;Safety evaluation;Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody	Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody;Safety evaluation;Safety evaluation;Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody
Feb. 28, 2021, 12:31 a.m.	usa	Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody;Safety evaluation;Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody	Geometric mean titer (GMT) of SARS-CoV-2 neutralizaing antibody;Safety evaluation;Seroconversion rate (SCR) of SARS-CoV-2 neutralizing antibody